NCT01672671View on ClinicalTrials.gov

BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

November 30, 2015

Conditions
Early Triple Negative Breast Cancer
Interventions
DRUG

Doxorubicin, Paclitaxel, Cisplatin

Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.

Trial Locations (1)

115478

Russian Cancer Research Center named after N.N.Blokhin RAMS, Moscow

All Listed Sponsors
lead

Russian Academy of Medical Sciences

OTHER

NCT01672671 - BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy | Biotech Hunter | Biotech Hunter